NCT06347965Completed
Construction and Effect Evaluation of the Low Load Blood Flow Restriction Training Program for Lung Cancer Patients Complicated With Sarcopenia During Chemotherapy
Source: ClinicalTrials.gov · Last updated 4 Apr 2024
Brief summary (registry, in English)
The goal of this clinical trial is to verify the effectiveness and safety of the low load blood flow restriction training program. The intervention effect, tolerance and compliance of low load blood flow restriction training and progressive resistance training on lung cancer patients complicated with sarcopenia during chemotherapy will be compared, in order to provide new ideas for improving or reversing sarcopenia. The main questions it aims to answer are: Can low load blood flow restriction training improve sarcopenia in chemotherapy induced lung cancer patients? Which training method is more effective and tolerable between low load blood flow restriction training and progressive resistance training? Participants will be randomly divided into 3 groups： 1. Routine care group (Control group, CON): The researchers will provide participants with regular exercise and dietary guidance. 2. Low load blood flow restriction group (LL-BFRT): The researchers will provide participants with a low load blood flow restriction training program constructed by our research group. 3. Progressive resistance training group (PRE): The researchers will provide participants with progressive resistance training.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 104 (actual)
- First submitted
- 28 Mar 2024
- Start date
- Feb 2023
- Primary completion date
- Nov 2023
- Lead sponsor
- Xin Wang
- Diseases
- Lung cancer
- NCT number
- NCT06347965
What you commit to
- Study type: Interventional
- Participants enrolled: 104
- From Feb 2023 to the primary completion date, Nov 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Merge with other malignant tumors
- Patients with cognitive impairment and mental illness
Lab values
- There are contraindications or symptoms or diseases that affect exercise, such as uncontrolled hypertension, venous thrombosis, infection, platelet count\<50 × 109/L, white blood cell count\<3.0 × 109/L, hemoglobin\<10 mg/dL, bleeding tendency, arrhythmia, heart failure, unstable angina, heart valve disease, chronic obstructive pulmonary disease, asthma, limb dysfunction, severe muscle, bone and joint diseases, etc
Other
- The risk factor score table for blood flow restriction training scores\>2
- During rest, blood oxygen saturation ≤ 90%
- Cannot conduct human body composition analyzer testing, such as for patients with cardiovascular stent implantation, pacemaker equipped, artificial joint replacement, or amputation
- Patients carrying PICC
- Patients with planned weight loss
Who the study is looking for
- The pathological diagnosis is lung cancer, and the diagnostic criteria refer to the 2023 edition of the Clinical Diagnosis and Treatment Guidelines for Lung Cancer of the Chinese Medical Association.
- Diagnosed as sarcopenia, the diagnostic criteria refer to the 2023 version of the Expert Consensus on the Diagnosis and Treatment of sarcopenia in the Elderly in China.
- Chemotherapy has been carried out and the remaining chemotherapy frequency is ≥ 4 times.
- Physical disability free, Eastern Cooperative Oncology Group Performance Status (ECOG PS) ≤ 2 points
- No language communication barriers, able to cooperate in completing scale assessments
- Expected life\>6 months
- Previous irregular exercise habits
- Patients and their families have informed consent and voluntarily join
- A person who has a smartphone and can complete WeChat check-in
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The First Affiliated Hospital Zhejiang University School of Medicine Coordinator of this site? Confirm its status | Hangzhou | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.